There are provisos that may prevent implementation of the the two executive orders with the greatest potential impact on pricing and patient out-of-pocket costs: International reference pricing for Medicare Part B drugs, and the rebate pass-through to Medicare Part D beneficiaries.
Trump’s Executive Orders On Drug Pricing Contain Caveats And Limitations
